🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

European regulator requests additional data related to Radius Health's marketing application for osteoporosis med Eladynos; Ad Com opinion expected year-end

Published 07/21/2017, 04:22 PM
© Reuters.  European regulator requests additional data related to Radius Health's marketing application for osteoporosis med Eladynos; Ad Com opinion expected year-end
RDUS_OLD
-
  • Radius Health (NASDAQ:RDUS) announces that the Committee for Medicinal Products for Human Use's (CHMP) scientific group has issued a second Day-180 List of Outstanding Issues regarding its Marketing Authorization Application (MAA) seeking approval of Eladynos (abaloparatide-SC) for the treatment of postmenopausal women with osteoporosis at high risk of fracture. The group has requested additional analyses related to the safety and efficacy data. The company intends to promptly respond to the issues. CHMP should issue an opinion by the end of the year.
  • If approved, it will be the first commercially available anabolic in Europe in 14 years. It was approved in the U.S. in April under the brand name TYMLOS.
  • Previously: FDA OKs Radius Health's osteoporosis med TYMLOS; shares up 11% (April 28)
  • Now read: An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.